logo
Plus   Neg
Share
Email

Pfizer, IDEAYA To Evaluate Clinical Combination Of IDE196 & Binimetinib

IDEAYA Biosciences, Inc. (IDYA) has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (PFE) for a clinical combination study of IDE196, and binimetinib, in GNAQ or GNA11 hotspot mutated solid tumors. IDEAYA will sponsor the study. Pfizer will supply binimetinib for the study. The trial is expected to begin in mid-2020.

"The prevalence of GNAQ or GNA11 hotspot mutations in Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, and other solid tumors represents approximately 6,000 patients in the U.S. and the five major European countries, and there are no approved targeted therapies for MUM or GNAQ/GNA11 hotspot mutation solid tumors," said Yujiro Hata, CEO, IDEAYA Biosciences.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MWE Investments is recalling dual fuel portable generators citing fire risk, according to the U.S. Consumer Product Safety Commission. The recall involves about 7,500 units of Westinghouse WGen5300DFv Dual Fuel Portable Generators and Westinghouse iGen4500DF Dual Fuel Inverter Portable Generators. According to the agency, the dual fuel portable generators can leak fuel. Apple Inc. (AAPL) will launch an online store in India on September 23, offering the tech giant's full range of products and support directly to customers across the country for the first time. U.S. retail sales continued to recover from the coronavirus pandemic in August, showing a slight improvement from July and larger gains than last year, the National Retail Federation or NRF said. However, the pace of growth slowed from July. The NRF said in a statement that August retail sales edged up 0.1 percent seasonally adjusted from July and rose 5.6 percent unadjusted year-over-year.
Follow RTT